Rationale, aims, and objectives: The United States is in the midst of a public health epidemic with more than 40 people dying each day from prescription opioid overdoses. Health care systems are taking steps to address the opioid overdose epidemic by implementing policy and practice interventions to mitigate the risks of long-term opioid therapy. Kaiser Permanente Southern California launched a comprehensive initiative to transform the way that chronic pain is viewed and treated. Kaiser Permanente Southern California created prescribing and dispensing policies, monitoring and follow-up processes, and clinical coordination through electronic health record integration. The purpose of this paper is to describe the implementation of these interventions and assess the impact of this set of interventions on opioid prescribing.
Beginning in the late 1990s, prescription opioids were increasingly used to treat pain-with an estimated 20% of patients presenting to physician offices with non-cancer pain symptoms or pain-related diagnoses receiving an opioid prescription. 2 In 2013, an estimated 1.9 million persons in the United States abused or were dependent on prescription opioid pain medication. 3 In 2015, there were more than 15 000 deaths involving prescription opioids,* in the United
States. 4 The 4-fold increase in deaths since 1999 parallels a concomitant increase in sales of opioid pain medications during the same period. 5 Among patients receiving opioid prescriptions for pain, higher opioid dosages are associated with increased risk of opioid overdose. [6] [7] [8] [9] A range of system-level strategies are being explored to alleviate the problem of inappropriate prescribing of opioids. 10 Interventions include the use of prescription drug monitoring programs, 11 restricting patients to a single pharmacy or provider, 12 state pill mill laws, 13 and patient and provider education. 14 2 | METHODS
| Evaluation design
Kaiser Permanente Southern California used a retrospective pre-post evaluation design to track these outcomes before and after the intervention:
• Reduce prescribing large quantities (>200 pills per prescription) of opioid-acetaminophen combination prescriptions
• Reduce prescribing high dose opioids (≥120 mg morphine milligram equivalent (MME) per day)
• Reduce combination prescribing of opioids with benzodiazepines and carisoprodol
• Less effective methods for implementing change (ie, traditional continuing medical education, didactic learning, and dissemination of materials) were intentionally de-emphasized. 20, 21 Interventions were introduced in a step-wise approach that allowed for refinements over time and a natural grouping of interventions. Also, interventions were rolled out first in smaller medical service areas and then adopted region wide. The interventions were standardized across the region by having common reports, letters, communications, templates, and implementation instructions. A brief description of the elements of the intervention is described in the next section.
The introduction of the interventions in years 2010 through 2015
and additional details about the efforts are in Table 1 .
Organizational support:
• Obtaining strong sponsorship from senior leaders in the Medical Group and pharmacy operations for this initiative;
• Forming a multi-disciplinary executive team composed of physician administrative leaders, clinical leaders from primary care, pain Oct Implemented corresponding responsibility: Escalation of Opioid Therapy Concerns Policy for outpatient pharmacists for all prescriptions for acetaminophen/opioid combination products >200 pills & any opioid prescription >1000 pills; or ≥120 MME/day (excluding cancer, palliative care and hospice) for all prescriptions for acetaminophen/opioid combination products and any opioid prescription Online chronic pain pharmacy training released 2014 Jan Created fentanyl prescribing memo implemented Emergency Department (ED) and urgent care practice change to no longer provide opioid injectables for exacerbations of chronic, non-cancer, non-hospice pain in urgent care and the emergency department based on American Academy of emergency medicine guideline Feb Finalized interdepartmental specialty support agreement with primary care Implemented "So long to Soma" initiative with training of all Drug education coordinators through academic detailers Apr Implemented emails based on EHR and KP prescription database to prescribers when high dose opioids patients have not had an office visit with the prescribing physician in 6 months or more and emails accompanied by a restatement of program goals, and applicable evidence and 2015 Jan Implemented National Pharmacy Controls Improvement Program: Provided pharmacy with tools (policies, monitoring, reporting, training, physical security) to comply with regulations on controlled substances Jun Updated pharmacy corresponding responsibility: Escalation of Opioid Therapy Concerns Policy for outpatient pharmacists to reflect changes: Red flags for ≥100 MME/day, any short-acting opioids >200 pills, any long acting opioid >400 pills Jul Implemented electronic prescribing of controlled substances implemented new comprehensive urine Drug screen for prescription and illegal drugs Oct Implemented hospital practice recommendations for inpatient patients on long-term opioid therapy on high dose opioids (≥100 MME/day) Dec Lowered 100 mg MME threshold to 60 mg MME for reporting and case review. [note: In march 2016, lowered to 50 mg MME/day based on the CDC Guideline for Prescribing Opioids for Chronic Pain. 
• Implementing inter-disciplinary controlled substances review teams in each Medical Center to oversee and support review of patients; receiving ≥120 MME per day (later reduced to ≥100 MME per day); and
• Developing opioids specialty support agreements between primary care and specialists.
Prescribing and dispensing policies:
• Implementing a self-imposed restriction policy for new prescribing of OxyContin (oxycodone-LA) and Opana (hydromorphone) to pain management, oncology, and continuing care clinicians (palliative and hospice care);
• Adding prescriptions of OxyContin and Opana to the list of highrisk medications limited to a 30-day supply, and patients are not allowed to refill these before 30 days;
• Avoiding daily doses of methadone (an alternative long acting opioid to OxyContin and Opana) ≥ 40 mg; †
• Instituting "Brand When Generic Available" initiative to reduce prescribing of brand name drugs when generics are available; and
• Encouraging prescribers to schedule office visits at least once every 6 months for patients on long-term opioid therapy (ie, prescribers were provided an individualized list of their patients who required a visit).
Performance feedback:
• Using prescribing data to generate prescriber-specific data on patients with high dose opioids accompanied by treatment and tapering recommendations based on best practices and clinical guidelines;
• Using EHR and prescribing data to send prescribers emails when patients on high dose opioids have not had an office visit with the prescribing physician in 8 months or more; and
• Instituting pharmacy calls to prescribers for high dosing to limit prescriptions to 200 pills for opioid-acetaminophen combination products and to 1000 pills for any opioids for all opioids, excluding cancer, hospice, and palliative care.
Prescriber education:
• Providing pain management continuing medical education to prescribers on current evidence-based pain assessment and safe opioid prescribing practices; and
• Implementing customized education sessions at KPSC's Medical Centers and one-on-one academic detailing using KPSC's leading pain and addiction specialists. 22 Decision support tools:
• Adding features to the EHR to provide medication menus, medication and safety alerts, questionnaires to inform prescribing physicians of the risks, preferred and maximum doses, links to evidence-based guidelines, prompts for alternative treatments or medications, and patient treatment agreements. Strived to ensure EHR alerts and pop-ups are optimized and do not interrupt work flow or introduce "alert fatigue" (ie, having too many alerts which could cause them to be ignored by prescribers); and several different MME conversion formulas for methadone. Kaiser Permanente Southern California chose a conversion factor for methadone that would be close to the 120 MME/day range, promoted by CMS. Using that, methadone 40 mg/day =120 MME/day, which at the time was the recommended maximum daily dose. In the years since, more consensuses have been adopted on the conversion of methadone; KPSC is in the process of adjusting the methadone maximum daily doses. Table 2 ).
As OxyContin-long acting (oxycodone-LA) and Opana All of these reductions were achieved with an ever changing patient population over 6 years.
There are limitations to this study. First, long-term health outcomes were not measured (ie, improved pain management and function; reduced prescription opioid overuse, misuse, abuse and addiction; reduced complications from opioids; and reduce unintentional overdose from opioids). As a next step in the research, it will be important to document the status of these measures, report how patient pain management and function was affected as prescribing was reduced, and if there were any unintended consequences.
Second, there are methodological limitations such as a pre-post design without having a comparison group, limited availability of pre-implementation data, and statistical analyses were determined to be beyond the scope of this preliminary investigation. Third, KPSC implemented a continuous quality improvement process over 6 years.
Many of these interventions occurred simultaneously. The relative contribution of any single intervention is unknown. Fourth, the KPSC population is reflective of a culturally diverse and insured population (including Medicaid, commercial, and Medicare) in southern California, so it is possible that the findings are not generalizable to uninsured populations or populations in other parts of the country. Despite these limitations, important lessons learned have been gleaned related to patient safety, multi-disciplinary engagement and corresponding responsibility, data-driven interventions and accountability, and generalizability. 
| Data-driven interventions and accountability
Continuous quality improvement over the 6 years-looking at data and tracking trends was a key driver. Local multi-disciplinary review teams compared actual practice with policies and gave providers data on their patients on high-risk regimens. Comparative performance feedback was also provided by sharing aggregate as well as provider-specific data. There was a commitment to develop measurement and analytic tools to support ongoing real time identification and monitoring of high utilizers. Through all of these touch-points, there was a cascade of accountability for performance improvement that emerged.
| Generalizability
The basic components of KPSC's intervention-prescribing and dispensing policies, provider education, clinical decision support tools, and organizational support-are potentially generalizable and applicable to other health care settings. These interventions can be done in any setting, as long as there is leadership commitment, multistakeholder collaboration and cooperation, as well as accurate and timely data. Certainly, the fully integrated health care delivery system of KPSC is an important contextual factor that offers inherent benefits to implementing a comprehensive system-level intervention. However, every health care system has its own culture and "way of doing business" that can be harnessed to help advance a similar initiative. While SAOP was implemented in a single region of one state and with an insured population, it is hoped that the interventions could be effective with different patient populations and in other states. Implementing these strategies in other settings will help assess their generalizability.
The United States is in the midst of a public health epidemic with more than 40 people dying each day from prescription opioid overdoses. Promising strategies such as those of KPSC demonstrate concrete ways to reduce inappropriate prescribing. Kaiser Permanente Southern California's systematic and evidence-based approach is changing the culture of pain management and opioid prescribing by "hard wiring" more effective, safer care into work flow through use of decision support, alerts, protocols, collaborative and integrated multi-specialty care, performance feedback, and ongoing communication about safer and appropriate opioid prescribing. Combining these strategies with efforts to collaborate with local and national effortssupport spread of safer prescribing, enhanced continuing education for providers, access to medication-assisted treatment, and increased availability, training, and use of naloxone-are ways to broaden the potential impact of health care system strategies. Continuing efforts to refine, evaluate, and strengthen these efforts are necessary to effectively reduce inappropriate opioid prescribing.
